{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:19:19Z","timestamp":1791091159212,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,4,29]],"date-time":"2012-04-29T00:00:00Z","timestamp":1335657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11910-012-0277-4","type":"journal-article","created":{"date-parts":[[2012,4,28]],"date-time":"2012-04-28T03:35:36Z","timestamp":1335584136000},"page":"359-366","source":"Crossref","is-referenced-by-count":23,"title":["Therapy in Huntington\u2019s Disease: Where Are We?"],"prefix":"10.1007","volume":"12","author":[{"given":"Martha A.","family":"Nance","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,29]]},"reference":[{"key":"277_CR1","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/mds.870110304","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. Unified Huntington\u2019s disease rating scale: reliability and consistency. Movement Disorders. 1996;11:236\u2013142.","journal-title":"Movement Disorders"},{"key":"277_CR2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","volume":"22","author":"SJ Tabrizi","year":"2012","unstructured":"Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24-month observational data. Lancet Neurol. 2012;22:42\u201353. This study of patients with HD, \u201cpremanifest\u201d gene-positive individuals, and controls demonstrates that the volume of both caudate nucleus and white matter are reduced in both patient groups compared with controls, and that changes in emotional recognition and speeded tapping tasks declined over 24\u00a0months in premanifest subjects..","journal-title":"Lancet Neurol"},{"key":"277_CR3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajmg.b.30970","volume":"153B","author":"A Semaka","year":"2010","unstructured":"Semaka A, Collins JA, Hayden MR. Unstable familial transmissions of Huntington disease alleles with 27\u201335 CAG repeats (intermediate alleles). Am J Med Genet B Neuropsychiatr Genet. 2010;153B:314\u201320.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"277_CR4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/B978-0-444-52014-2.00012-4","volume":"100","author":"G Kleiner-Fisman","year":"2011","unstructured":"Kleiner-Fisman G. Benign hereditary chorea. Handb Clin Neurol. 2011;100:199\u2013212.","journal-title":"Handb Clin Neurol"},{"key":"277_CR5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archneur.64.6.813","volume":"64","author":"P Riba\u012d","year":"2007","unstructured":"Riba\u012d P, Nguyen K, Hahn-Barma V, et al. Psychiatric and cognitive difficulties as indicators of juvenile Huntington disease onset in 29 patients. Arch Neurol. 2007;64:813\u20139. This study gives voice to something that parents have observed for years: the first symptom of HD in an adolescent can be severe psychological or cognitive, and not motor. Physicians remain reluctant to diagnose HD in the absence of a movement disorder..","journal-title":"Arch Neurol"},{"key":"277_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1037\/a0020937","volume":"25","author":"JC Stout","year":"2011","unstructured":"Stout JC, Paulsen JS, Queller S, et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology. 2011;25:1\u201314.","journal-title":"Neuropsychology"},{"key":"277_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2010.208264","volume":"82","author":"EH Aylward","year":"2011","unstructured":"Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatr. 2011;82:405\u201310. This is one of a series of papers from the PREDICT-HD group documenting radiologic changes in the brain in gene-positive patients who are not yet diagnosed with HD, referred to as having \u201cprodromal HD.\u201d.","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"277_CR8","doi-asserted-by":"crossref","first-page":"RRN1242","DOI":"10.1371\/currents.RRN1242","volume":"3","author":"AL Vaccarino","year":"2011","unstructured":"Vaccarino AL, Sills T, Anderson KE, et al. Assessment of depression, anxiety, and apathy in prodromal and early Huntington disease. PLoS Curr. 2011;3:RRN1242.","journal-title":"PLoS Curr"},{"key":"277_CR9","doi-asserted-by":"crossref","first-page":"RRN1250","DOI":"10.1371\/currents.RRN1250","volume":"3","author":"AL Vaccarino","year":"2011","unstructured":"Vaccarino AL, Sills T, Anderson KE, et al. Assessment of cognitive symptoms in prodromal and early Huntington disease. PLoS Curr. 2011;3:RRN1250.","journal-title":"PLoS Curr"},{"key":"277_CR10","doi-asserted-by":"crossref","first-page":"RRN1244","DOI":"10.1371\/currents.RRN1244","volume":"2","author":"AL Vaccarino","year":"2011","unstructured":"Vaccarino AL, Sills T, Anderson KE, et al. Assessment of motor and functional impact in prodromal and early Huntington disease. PLoS Curr. 2011;2:RRN1244.","journal-title":"PLoS Curr"},{"key":"277_CR11","doi-asserted-by":"crossref","first-page":"RRN1262","DOI":"10.1371\/currents.RRN1262","volume":"3","author":"AL Vaccarino","year":"2011","unstructured":"Vaccarino AL, Sills T, Anderson KE, et al. Assessment of day-to-day functioning in prodromal and early Huntington disease. PLoS Curr. 2011;3:RRN1262.","journal-title":"PLoS Curr"},{"key":"277_CR12","doi-asserted-by":"crossref","unstructured":"Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington\u2019s disease. Cochrane Database Syst Rev 2009:CD006456. This is a systematic Cochrane review of the prior literature on pharmacotherapy in HD.","DOI":"10.1002\/14651858.CD006456.pub2"},{"key":"277_CR13","doi-asserted-by":"crossref","unstructured":"Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington\u2019s disease. Cochrane Database Syst Rev 2009:CD006455.","DOI":"10.1002\/14651858.CD006455.pub2"},{"key":"277_CR14","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","volume":"12","author":"RM Bonelli","year":"2006","unstructured":"Bonelli RM, Wenning GK. Pharmacological management of Huntington\u2019s disease: an evidence-based review. Curr Pharm Des. 2006;12:2701\u201320.","journal-title":"Curr Pharm Des"},{"key":"277_CR15","doi-asserted-by":"crossref","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","volume":"3","author":"JM Burgunder","year":"2011","unstructured":"Burgunder JM, Guttman M, Perlman S, et al. An international survey-based algorithm for the pharmacological treatment of chorea in Huntington\u2019s disease. PLoS Curr. 2011;3:RRN1260. This study, along with the next two references, represents an attempt to understand current management strategies among an international group of HD experts.","journal-title":"PLoS Curr"},{"key":"277_CR16","doi-asserted-by":"crossref","first-page":"RRN1259","DOI":"10.1371\/currents.RRN1259","volume":"3","author":"M Groves","year":"2011","unstructured":"Groves M, van Duijn E, Anderson K, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington\u2019s disease. PLoS Curr. 2011;3:RRN1259.","journal-title":"PLoS Curr"},{"key":"277_CR17","doi-asserted-by":"crossref","first-page":"RRN1261","DOI":"10.1371\/currents.RRN1261","volume":"3","author":"K Anderson","year":"2011","unstructured":"Anderson K, Craufurd D, Edmondson MC, et al. An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington\u2019s disease. PLoS Curr. 2011;3:RRN1261.","journal-title":"PLoS Curr"},{"key":"277_CR18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366\u201372.","journal-title":"Neurology"},{"key":"277_CR19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","volume":"9","author":"S Frank","year":"2009","unstructured":"Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. BMC Neurol. 2009;9:62.","journal-title":"BMC Neurol"},{"key":"277_CR20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","volume":"33","author":"A Lundin","year":"2010","unstructured":"Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR 16) in patients with Huntington\u2019s disease. Clin Neuropharmacol. 2010;33:260\u20134.","journal-title":"Clin Neuropharmacol"},{"key":"277_CR21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","volume":"10","author":"JG Yebenes De","year":"2011","unstructured":"De Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington\u2019s disease (MermaiHD): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10:1049\u201357.","journal-title":"Lancet Neurol"},{"key":"277_CR22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000327754","volume":"8","author":"JG Fiedorowicz","year":"2011","unstructured":"Fiedorowicz JG, Mills JA, Ruggle A, et al. Suicidal behavior in prodromal Huntington disease. Neurodegener Dis. 2011;8:483\u201390.","journal-title":"Neurodegener Dis"},{"key":"277_CR23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.psychres.2011.05.006","volume":"188","author":"HH Wetzel","year":"2011","unstructured":"Wetzel HH, Gehl CR, Dellefave-Castillo L, et al. Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res. 2011;188:372\u20136.","journal-title":"Psychiatry Res"},{"key":"277_CR24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","volume":"25","author":"AK Holl","year":"2010","unstructured":"Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington\u2019s disease: effective treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25:46\u201350.","journal-title":"Int Clin Psychopharmacol"},{"key":"277_CR25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/NMD.0b013e3181da852a","volume":"198","author":"KI Anderson","year":"2010","unstructured":"Anderson KI, Gehl CR, Marder KS, et al. Comorbidities of obsessive and compulsive symptoms in Huntington\u2019s disease. J Nerv Ment Dis. 2010;198:334\u20138.","journal-title":"J Nerv Ment Dis"},{"key":"277_CR26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s11940-011-0140-y","volume":"13","author":"A Krishnamoorthy","year":"2011","unstructured":"Krishnamoorthy A, Craufurd D. Treatment of apathy in Huntington\u2019s disease and other movement disorders. Curr Treat Options Neurol. 2011;13:508\u201319.","journal-title":"Curr Treat Options Neurol"},{"key":"277_CR27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/YIC.0b013e3283407775","volume":"26","author":"TG Johnston","year":"2011","unstructured":"Johnston TG. Risperidone long-acting injection and Huntington\u2019s disease with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol. 2011;26:114\u20139.","journal-title":"Int Clin Psychopharmacol"},{"key":"277_CR28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/JCP.0b013e3181b2ac0a","volume":"29","author":"LJ Beglinger","year":"2009","unstructured":"Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29:484\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"277_CR29","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","volume":"67","author":"E Cubo","year":"2006","unstructured":"Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67:1268\u201371.","journal-title":"Neurology"},{"key":"277_CR30","unstructured":"Medivation, Inc. Press release. http:\/\/investors.medication.com\/releasedetail.cfm?ReleaseID=567758 . Accessed February 12, 2012."},{"key":"277_CR31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.wnf.0000240945.44370.f0","volume":"30","author":"M Tomasso de","year":"2007","unstructured":"de Tomasso M, Difruscolo O, Sciruicchio V, et al. Two years\u2019 follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30:43\u20136.","journal-title":"Clin Neuropharmacol"},{"key":"277_CR32","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/mds.22408","volume":"25","author":"HC Hyson","year":"2010","unstructured":"Huntington Study Group Pre2CARE Investigators, Hyson HC, Kieburtz K, et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington\u2019s disease and healthy subjects. Mov Disord. 2010;25:1924\u20138.","journal-title":"Mov Disord"},{"key":"277_CR33","unstructured":"European Huntington\u2019s Disease Network. Physiotherapy Guidance Document. http:\/\/www.euro-hd.net\/html\/network\/groups\/physio\/physiotherapy-guidance-doc-2009.pdf?tm=1329067572 . Accessed February 12, 2012. This document not only summarizes in detail every study ever done, but also includes many of the recommended rating scales, and provides practical advice for physical therapists in the clinic with an HD patient."},{"key":"277_CR34","doi-asserted-by":"crossref","first-page":"RRN1268","DOI":"10.1371\/currents.RRN1268","volume":"3","author":"AK Rao","year":"2011","unstructured":"Rao AK, Mazzoni P, Wasserman P, Marder K. Longitudinal change in gait and motor function in pre-manifest Huntington\u2019s disease. PLoS Curr. 2011;3:RRN1268.","journal-title":"PLoS Curr"},{"key":"277_CR35","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/mds.22003","volume":"23","author":"YA Grimbergen","year":"2008","unstructured":"Grimbergen YA, Knol MJ, Bloem BR, et al. Falls and gait disturbances in Huntington\u2019s disease. Mov Disord. 2008;23:970\u20136.","journal-title":"Mov Disord"},{"key":"277_CR36","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/mds.23421","volume":"25","author":"AD Kloos","year":"2010","unstructured":"Kloos AD, Kegelmeyer DA, Young GS, Kostyk SK. Fall risk using the Tinetti mobility test in individuals with Huntington\u2019s disease. Mov Disord. 2010;25:2838\u201344.","journal-title":"Mov Disord"},{"key":"277_CR37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jns.2010.08.002","volume":"298","author":"A Goldberg","year":"2010","unstructured":"Goldberg A, Schepens SL, Feely SM, et al. Deficits in stepping response time are associated with impairments in balance and mobility in people with Huntington disease. J Neurol Sci. 2010;298:92\u20135.","journal-title":"J Neurol Sci"},{"key":"277_CR38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2522\/ptj.20100438","volume":"92","author":"H Khalil","year":"2012","unstructured":"Khalil H, Quinn L, van Duersen R, et al. Adherence to use of a home-based exercise DV D in people with Huntington disease: participants\u2019 perspectives. Phys Ther. 2012;92:69\u201382.","journal-title":"Phys Ther"},{"key":"277_CR39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269215507075495","volume":"21","author":"P Zinzi","year":"2007","unstructured":"Zinzi P, Salmaso D, De Grandis R, et al. Effects of an intensive rehabilitation programme on patients with Huntington\u2019s disease: a pilot study. Dlin Rehabil. 2007;21:603\u201313.","journal-title":"Dlin Rehabil"},{"key":"277_CR40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainresbull.2009.06.017","volume":"80","author":"RB Veenhuizen","year":"2009","unstructured":"Veenhuizen RB, Tibben A. Coordinated multidisciplinary care for Huntington\u2019s disease. An outpatient department. Brain Res Bull. 2009;80:192\u20135.","journal-title":"Brain Res Bull"},{"key":"277_CR41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-6-77","volume":"6","author":"RB Veenhuizen","year":"2011","unstructured":"Veenhuizen RB, Kootstra B, Vink W, et al. Coordinated multidisciplinary care for ambulatory Huntington\u2019s disease patients. Evaluation of 18\u00a0months of implementation. Orphanet J Rare Dis. 2011;6:77.","journal-title":"Orphanet J Rare Dis"},{"key":"277_CR42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/09638288.2010.487924","volume":"33","author":"JA Spring","year":"2011","unstructured":"Spring JA, Baker M, Dauya L, et al. Gardening with Huntington\u2019s disease clients\u2014creating a programme of winter activities. Disabil Rehabil. 2011;33:159\u201364.","journal-title":"Disabil Rehabil"},{"key":"277_CR43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/mds.870110509","volume":"11","author":"MA Nance","year":"1996","unstructured":"Nance MA, Sanders G. Characteristics of individuals with Huntington disease in long-term care. Mov Disord. 1996;11:542\u20138.","journal-title":"Mov Disord"},{"key":"277_CR44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00455-010-9302-4","volume":"26","author":"AW Heemskerk","year":"2011","unstructured":"Heemskerk AW, Roos RA. Dysphagia in Huntington\u2019s disease: a review. Dysphagia. 2011;26:62\u20136. This nicely written review documents the sad state of the previous literature on dysphagia in HD, which should suggest an important path for future research..","journal-title":"Dysphagia"},{"key":"277_CR45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1179\/147683008X344129","volume":"11","author":"A Gaba","year":"2008","unstructured":"Gaba A, Zhang K, Moskowitz, et al. Harris-Benedict equation estimations of energy needs as compared to measured 24-hour energy expenditure by indirect calorimetry in early to mid-stage Huntington\u2019s disease. Nutr Neurosci. 2008;11:213\u20138.","journal-title":"Nutr Neurosci"},{"key":"277_CR46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nut.2003.10.007","volume":"20","author":"A Trejo","year":"2004","unstructured":"Trejo A, Tarrats RM, Alonso. Assessment of the nutrition status of patients with Huntington\u2019s disease. Nutrition. 2004;20:192\u20136.","journal-title":"Nutrition"},{"key":"277_CR47","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.nut.2004.12.012","volume":"21","author":"A Trejo","year":"2005","unstructured":"Trejo A, Boll MC, Alonso ME, et al. Use of oral nutritional supplements in patients with Huntington\u2019s disease. Nutrition. 2005;21:889\u201394.","journal-title":"Nutrition"},{"key":"277_CR48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1017\/S1478951511000393","volume":"9","author":"E Wilson","year":"2011","unstructured":"Wilson E, Seymour J, Aubeeluck A. Perspectives of staff providing care at the end of life for people with progressive neurological conditions. Palliat Support Care. 2011;9:377\u201385.","journal-title":"Palliat Support Care"},{"key":"277_CR49","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/JNN.0b013e3182212a52","volume":"43","author":"ME Dellefield","year":"2011","unstructured":"Dellefield ME, Ferrini R. Promoting excellence in end-of-life care: lessons learned from a cohort of nursing home residents with advanced Huntington disease. J Neurosci Nurs. 2011;43:186\u201392. This is a review of one group\u2019s clinical experience, which leads to thoughtful and practical suggestions for those caring for people with late-stage HD..","journal-title":"J Neurosci Nurs"},{"key":"277_CR50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1891\/1521-0987.9.2.75","volume":"9","author":"J Klager","year":"2008","unstructured":"Klager J, Duckett A, Sandler S, Moskowitz C. Huntington\u2019s disease: a caring approach to the end of life. Care Manag J. 2008;9:75\u201381.","journal-title":"Care Manag J"},{"key":"277_CR51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.12968\/ijpn.2007.13.3.23274","volume":"13","author":"E Travers","year":"2007","unstructured":"Travers E, Jones K, Nichol J. Palliative care provision in Huntington\u2019s disease. Int J Palliat Nurs. 2007;13:125\u201330.","journal-title":"Int J Palliat Nurs"},{"key":"277_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/J354v20n04_18","volume":"20","author":"WM Lamers","year":"2006","unstructured":"Lamers WM. Huntington\u2019s chorea, leukemia at end-of-life, G-tubes, open access to hospice. J Pain Palliat Care Pharmacother. 2006;20:89\u201392.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"277_CR53","unstructured":"http:\/\/www.hdsa.org\/living-with-huntingtons\/resources\/centers-of-excellence\/index.html . accessed February, 2012."},{"key":"277_CR54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2702.2007.02276.x","volume":"17","author":"B Soltysiak","year":"2008","unstructured":"Soltysiak B, Gardiner P, Skirton H. Exploring supportive care for individuals affected by Huntington disease and their family caregivers in a community setting. J Clin Nurs. 2008;17:226\u201334.","journal-title":"J Clin Nurs"},{"key":"277_CR55","doi-asserted-by":"crossref","first-page":"328","DOI":"10.12968\/bjon.2008.17.5.28830","volume":"17","author":"A Aubeeluck","year":"2008","unstructured":"Aubeeluck A, Moskowitz CB. Huntington\u2019s disease. Part 3. Family aspects. Br J Nurs. 2008;17:328\u201331.","journal-title":"Br J Nurs"},{"key":"277_CR56","unstructured":"Schwartz RR. Ripples from a stone skipping across the lake: a narrative approach to the meaning of Huntington\u2019s disease."},{"key":"277_CR57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1442-2018.2004.00183.x","volume":"6","author":"S Dawson","year":"2004","unstructured":"Dawson S, Kristjanson LJ, Toye CM, Flett P. Living with Huntington\u2019s disease: need for supportive care. Nurs Health Sci. 2004;6:123\u201330.","journal-title":"Nurs Health Sci"},{"key":"277_CR58","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.brainresbull.2006.10.023","volume":"30","author":"A Tibben","year":"2007","unstructured":"Tibben A. Predictive testing for Huntington\u2019s disease. Brain Res Bull. 2007;30:165\u201371.","journal-title":"Brain Res Bull"},{"key":"277_CR59","doi-asserted-by":"crossref","unstructured":"Van Rij MC, De Rademaeker M, Moutou C, et al. Preimplantation genetic diagnosis (PGD) for Huntington\u2019s disease: the experience of three European centres. Eur J Hum Genet 2011. doi: 10.1038\/ejhg.2011.202 .","DOI":"10.1038\/ejhg.2011.202"},{"key":"277_CR60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1742395311403637","volume":"7","author":"H Etchegary","year":"2011","unstructured":"Etchegary H. Healthcare experiences of families affected by Huntington disease: need for improved care. Chronic Illn. 2011;7:225\u201338.","journal-title":"Chronic Illn"},{"key":"277_CR61","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2648.2009.05217.x","volume":"66","author":"H Skirton","year":"2010","unstructured":"Skirton H, Williams JK, Jackson Barnette J, Paulsen JS. Huntington disease: families\u2019 experiences of healthcare services. J Adv Nurs. 2010;66:500\u201310.","journal-title":"J Adv Nurs"},{"key":"277_CR62","volume-title":"A physician\u2019s guide to the management of Huntington\u2019s disease","author":"M Nance","year":"2011","unstructured":"Nance M, Paulsen JS, Rosenblatt A, Wheelock V. A physician\u2019s guide to the management of Huntington\u2019s disease. 3rd ed. New York: Huntington\u2019s Disease Society of America; 2011. This is a clinical guide for the treating physician, written by two neurologists, a neuropsychologist, and a psychiatrist with close to 100 years of collective experience with HD patients and families..","edition":"3"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0277-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-012-0277-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-012-0277-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:08:57Z","timestamp":1713917337000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-012-0277-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,29]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["277"],"URL":"https:\/\/doi.org\/10.1007\/s11910-012-0277-4","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,29]]}}}